May 27, 2011 by Brian Orelli, PhDWhat Kind of Phase 2 Drug Can You Get for $5 Million?Cell Therapeutics goes trash diving.
May 26, 2011 by Brian Orelli, PhDCongress Sets Bad Precedent With AVANIRWhat happened to free markets?
May 26, 2011 by Brian Orelli, PhDIntriguing, Potentially Lucrative, But Still Not Worth the Jump in SharesElan sets up a drug development deal with Proteostasis.
May 25, 2011 by Brian Orelli, PhDSatisfying Clinical Trial Straightens Up SharesVIVUS' erectile dysfunction drug avanafil works.
May 25, 2011 by Brian Orelli, PhDNo Red Carpet for Medtronic's New CEOOmar Ishrak inherits slow growth.
May 25, 2011 by Brian Orelli, PhDOptimer's Upcoming FDA Decision: Memorable or Memorial?We'll know on Memorial Day, plus or minus a few days.
May 24, 2011 by Brian Orelli, PhDJ&J Approved, but Needs Help From a FriendThe HIV combo product is the key.
May 24, 2011 by Brian Orelli, PhDIf at First You Don't Succeed, Spin It OffEli Lilly ditches Xigris by spinning off BioCritica.
May 23, 2011 by Brian Orelli, PhDThe Clash of the Hep C Drugs Can BeginVertex's and Merck's drugs hit the market.
May 20, 2011 by Brian Orelli, PhDAbbott Hits a TripleNot a home run, but Trilipix will likely stay on the market.
May 20, 2011 by Brian Orelli, PhDThe Big Winner of the EU Drug Approval BonanzaSix drug approvals in one day. Oh my!
May 19, 2011 by Brian Orelli, PhDPfizer Goes for a One-Two Blockbuster KnockoutAxitinib beats Nexavar in a head-to-head trial.
May 18, 2011 by Brian Orelli, PhD5 Biotech ASCO Abstracts to WatchChristmas in May for biotech investors.
May 18, 2011 by Brian Orelli, PhDIf You Can't Beat 'Em, Use 'Em to Beat Your New RivalMerck and Roche team up.
May 18, 2011 by Brian Orelli, PhDMore Data, Same ControversyWill Amgen's Xgeva be used to delay bone metastasis?
May 17, 2011 by Brian Orelli, PhD$3 Million Here, $1.5 Billion ThereIsis makes progress in its pact with GlaxoSmithKline.
May 16, 2011 by Brian Orelli, PhDDiabetes Drug Duo Duels It Out in CourtAmylin sticks up to partner Eli Lilly.
May 13, 2011 by Brian Orelli, PhDFDA Advisory Panel Positive! Shares Punished.Despite the positive recommendation, investors aren't convinced BioMimetic's Augment will be approved.
